Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
暂无分享,去创建一个
Merlin C. Thomas | Merlin C Thomas | M. Cooper | W. Burns | J. Forbes | A. Calkin | R. Candido | K. Jandeleit-Dahm | T. Allen | V. Thallas | M. Lassila | Kwee K Seah | M. Thomas | M. Cooper | Wendy C. Burns
[1] G. Jerums,et al. The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[3] J. Baynes,et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. , 2003, Kidney international.
[4] Merlin C. Thomas,et al. A Breaker of Advanced Glycation End Products Attenuates Diabetes‐Induced Myocardial Structural Changes , 2003, Circulation research.
[5] V. D’Agati,et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.
[6] A. Enomoto,et al. An inhibitor of advanced glycation end product formation reducesNϵ-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats , 2003 .
[7] Hiroshi Yamamoto,et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. , 2003, Journal of diabetes and its complications.
[8] A. Enomoto,et al. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] G. King,et al. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. , 2002, JAMA.
[10] Merlin C. Thomas,et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. , 2002, Diabetes.
[11] M. Matsuda,et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] C. Alpers,et al. Renal Injury in Apolipoprotein E–Deficient Mice , 2002, Laboratory Investigation.
[13] M. Cooper,et al. Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice , 2002, Circulation.
[14] M. Cooper,et al. Materials and Methods Protocol 1 : Assessment of AT 1 and AT 2 Receptor Expression in the Remnant Kidney , 2002 .
[15] H. Vlassara,et al. Diabetes and advanced glycation endproducts , 2002, Journal of internal medicine.
[16] L. Paka,et al. A Protective Role for Kidney Apolipoprotein E , 2001, The Journal of Biological Chemistry.
[17] R. Atkins,et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.
[18] M. Brownlee. Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.
[19] A. Fujimura,et al. Effect Of Enalapril On Diabetic Nephropathy In Oletf Rats: The Role Of An Anti‐Oxidative Action In Its Protective Properties , 2001, Clinical and experimental pharmacology & physiology.
[20] V. D’Agati,et al. Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[21] M. Cooper,et al. Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion , 2001, Journal of hypertension.
[22] G. Jerums,et al. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. , 2000, Journal of the American Society of Nephrology : JASN.
[23] B. Kasiske,et al. Effect of lipid reduction on the progression of renal disease: a meta-analysis. , 2001, Kidney international.
[24] D. Moczulski,et al. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. , 2000, Diabetes.
[25] V. D’Agati,et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.
[26] G. Brabant,et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. , 2000, Kidney international.
[27] M. Cooper,et al. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. , 1999, Kidney international. Supplement.
[28] T. Hirano. Lipoprotein abnormalities in diabetic nephropathy. , 1999, Kidney international. Supplement.
[29] M. Neurath,et al. RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.
[30] M. Cooper,et al. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). , 1998, Kidney international.
[31] M. Huijberts,et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[32] G. Jerums,et al. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. , 1998, Diabetes.
[33] G. Jerums,et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats , 1997, Diabetologia.
[34] J. Malacara,et al. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. , 1997, Clinical chemistry.
[35] G. Becker,et al. Myofibroblasts and arteriolar sclerosis in human diabetic nephropathy. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] C. Brown,et al. Myofibroblasts and the progression of diabetic nephropathy. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] A. Krolewski,et al. Apolipoprotein E genotypes and risk of diabetic nephropathy. , 1996, Journal of the American Society of Nephrology : JASN.
[38] T. Lyons,et al. The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.
[39] H. Rasmussen,et al. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. , 1995, Kidney international.
[40] J. Hodgin,et al. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.
[41] A. Krolewski,et al. Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy. , 1994, Kidney international. Supplement.
[42] M. Laakso,et al. Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. , 1993, Atherosclerosis.
[43] M. Mcdaniel,et al. Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation , 1993, Diabetes.
[44] V. Monnier,et al. Pentosidine Formation in Skin Correlates With Severity of Complications in Individuals With Long-Standing IDDM , 1992, Diabetes.
[45] G. Jerums,et al. Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.
[46] G. Jerums,et al. Glomerular Filtration Rate in Streptozocin-Induced Diabetic Rats: Role of Exchangeable Sodium, Vasoactive Hormones, and Insulin Therapy , 1990, Diabetes.
[47] D. Hume,et al. Mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. , 1983 .